change with same therapeutic target (SWITCH) and drug change with different therapeutic target (SWAP). The Studentś t test for correlated groups was performed but any intervention involving SWAP or SWITCH was excluded. Asymptomatic patients without altered APR and optimal plasma adalimumab concentrations maintained the same treatment scheme. Results 89 patients were analysed and 41 (46%) patients were proposed and accepted for interventions, of whom 22 (54%) were men with a mean age of 40 years (18-66). The data are shown in table 1. Interventions performed: 21 (51%) deintensification, 10 (24%) intensification, 7 (17%) SWAP and 3 (7%) SWITCH. Symptomatic patients before interventions totalled 19 (46%); after the interventions 4 (10%) patients remained symptomatic, 3 after intensification and 1 after a treatment SWITCH. Conclusion and relevance APR improved after interventions. Faecal calprotectin showed a significative p value. Further studies are required. Monitoring adalimumab along with clinical patient data is crucial to optimise IBD control. This practice is effective, safe and contributes to the sustainability of the health system, saving possible adverse effects and money. Clinical pharmacists have a crucial role in optimal clinical patient development.

No abstract

change with same therapeutic target (SWITCH) and drug change with different therapeutic target (SWAP). The Studentś t test for correlated groups was performed but any intervention involving SWAP or SWITCH was excluded. Asymptomatic patients without altered APR and optimal plasma adalimumab concentrations maintained the same treatment scheme. Results 89 patients were analysed and 41 (46%) patients were proposed and accepted for interventions, of whom 22 (54%) were men with a mean age of 40 years (18-66). The data are shown in table 1. Interventions performed: 21 (51%) deintensification, 10 (24%) intensification, 7 (17%) SWAP and 3 (7%) SWITCH. Symptomatic patients before interventions totalled 19 (46%); after the interventions 4 (10%) patients remained symptomatic, 3 after intensification and 1 after a treatment SWITCH. Conclusion and relevance APR improved after interventions. Faecal calprotectin showed a significative p value. Further studies are required. Monitoring adalimumab along with clinical patient data is crucial to optimise IBD control. This practice is effective, safe and contributes to the sustainability of the health system, saving possible adverse effects and money. Clinical pharmacists have a crucial role in optimal clinical patient development.